DDMC-p53 gene therapy with or without cisplatin and microwave ablation

Wolfgang Hohenforst-Schmidt; Paul Zarogoulidis; Joshua Stopek; Thomas Vogl; Frank Hübner; J Francis Turner; Robert Browning; Konstantinos Zarogoulidis; Antonis Drevelegas; Konstantinos Drevelegas; Kaid Darwiche; Lutz Freitag; Harald Rittger

doi:10.2147/OTT.S83794

DDMC-p53 gene therapy with or without cisplatin and microwave ablation

Onco Targets Ther. 2015 May 20:8:1165-73. doi: 10.2147/OTT.S83794. eCollection 2015.

Affiliations

¹ II Medical Clinic, Coburg Hospital, University of Wuerzburg, Coburg, Germany.
² Pulmonary Department-Oncology Unit, G Papanikolaou General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
³ Covidien, Jersey City, NJ, USA.
⁴ Department of Diagnostic and Interventional Radiology, Goethe University of Frankfurt, Frankfurt, Germany.
⁵ Division of Interventional Pulmonology, Western Regional Medical Center, Goodyear, AZ ; Medical Oncology, Cancer Treatment Centers of America, Western Regional Medical Center, Goodyear, AZ.
⁶ Pulmonary and Critical Care Medicine, Interventional Pulmonology, National Naval Medical Center, Walter Reed Army Medical Center, Bethesda, MD, USA.
⁷ Radiology Department, Interbalkan European Medical Center, Thessaloniki, Greece.
⁸ Department of interventional Pneumology, Ruhrlandklinik, University Hospital Essen, University of Essen-Duisburg, Essen, Germany.
⁹ Medical Clinic I, 'Fuerth Hospital, University of Erlangen, Erlangen, Germany.

Abstract

Lung cancer remains the leading cause of death in cancer patients. Severe treatment side effects and late stage of disease at diagnosis continue to be an issue. We investigated whether local treatment using 2-diethylaminoethyl-dextran methyl methacrylate copolymer with p53 (DDMC-p53) with or without cisplatin and/or microwave ablation enhances disease control in BALBC mice. We used a Lewis lung carcinoma cell line to inoculate 140 BALBC mice, which were divided into the following seven groups; control, cisplatin, microwave ablation, DDMC-p53, DDMC-p53 plus cisplatin, DDMC-p53 plus microwave, and DDMC-p53 plus cisplatin plus microwave. Microwave ablation energy was administered at 20 W for 10 minutes. Cisplatin was administered as 1 mL/mg and the DDMC-p53 complex delivered was 0.5 mL. Increased toxicity was observed in the group receiving DDMC-p53 plus cisplatin plus microwave followed by the group receiving DDMC-p53 plus cisplatin. Infection after repeated treatment administration was a major issue. We conclude that a combination of gene therapy using DDMC-p53 with or without cisplatin and microwave is an alternative method for local disease control. However, more experiments are required in a larger model to identify the appropriate dosage profile.

Keywords: DDMC; carboplatin; microwave; non-small cell lung cancer; p53.